Top

18-12-2024 | Breast Cancer | REVIEW ARTICLE

Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles

Authors: Faris Anad Muhammad, Farag M. A. Altalbawy, Viralkumar Mandaliya, Shelesh Krishna Saraswat, M. M. Rekha, Damanjeet Aulakh, Mamata Chahar, Morug Salih Mahdi, Mohammed Adil Jaber, Merwa Alhadrawi

Published in: Clinical and Translational Oncology

Abstract

Breast cancer is a complicated malignancy and is known as the most common cancer in women. Considerable experiments have been devoted to explore the basic impacts of the tumor stroma, particularly the extracellular matrix (ECM) and stromal components, on tumor growth and resistance to treatment. ECM is made up of an intricate system of proteins, glycosaminoglycans, and proteoglycans, and maintains structural support and controls key signaling pathways involved in breast tumors. ECM can block different drugs such as chemotherapy and immunotherapy drugs from entering the tumor stroma. Furthermore, the stromal elements, such as cancer-associated fibroblasts (CAFs), immune cells, and blood vessels, have crucial impacts on tumor development and therapeutic resistance. Recently, promising outcomes have been achieved in using nanotechnology for delivering drugs to tumor stroma and crossing ECM in breast malignancies. Nanoparticles have various benefits for targeting the breast tumor stroma, such as improved permeability and retention, extended circulation time, and the ability to actively target the area. This review covers the latest developments in nanoparticle therapies that focus on breast tumor ECM and stroma. We will explore different approaches using nanoparticles to target the delivery of anticancer drugs like chemotherapy, small molecule drugs, various antitumor products, and other specific synthetic therapeutic agents to the breast tumor stroma. Furthermore, we will investigate the utilization of nanoparticles in altering the stromal elements, such as reprogramming CAFs and immune cells, and also remodeling ECM.

Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–41.PubMedCrossRef

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. The Breast. 2022;66:15–23.PubMedPubMedCentralCrossRef

Trayes KP, Cokenakes SE. Breast cancer treatment. Am Fam Phys. 2021;104(2):171–8.

Khodamoradi E, Hoseini-Ghahfarokhi M, Amini P, Motevaseli E, Shabeeb D, Musa AE, et al. Targets for protection and mitigation of radiation injury. Cell Mol Life Sci. 2020;77(16):3129–59. https://doi.org/10.1007/s00018-020-03479-x.CrossRefPubMedPubMedCentral

Luque-Bolivar A, Pérez-Mora E, Villegas VE, Rondón-Lagos M. Resistance and overcoming resistance in breast cancer. Breast Cancer (London). 2020;12:211–29.

Mortezaee K, Najafi M, Farhood B, Ahmadi A, Shabeeb D, Musa AE. Resveratrol as an adjuvant for normal tissues protection and tumor sensitization. Curr Cancer Drug Targets. 2020;20(2):130–45. https://doi.org/10.2174/1568009619666191019143539.CrossRefPubMed

Xu M, Zhang T, Xia R, Wei Y, Wei X. Targeting the tumor stroma for cancer therapy. Mol Cancer. 2022;21(1):208.PubMedPubMedCentralCrossRef

Rodrigues J, Heinrich MA, Teixeira LM, Prakash J. 3D in vitro model (R) evolution: unveiling tumor–stroma interactions. Trends Cancer. 2021;7(3):249–64.PubMedCrossRef

Vangangelt KM, Green AR, Heemskerk IM, Cohen D, Van Pelt GW, Sobral-Leite M, et al. The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. Int J Cancer. 2020;146(8):2296–304.PubMedPubMedCentralCrossRef

10.

Zhang M, Gao S, Yang D, Fang Y, Lin X, Jin X, et al. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. Acta Pharmaceutica Sinica B. 2021;11(8):2265–85.PubMedPubMedCentralCrossRef

11.

Saadh MJ, Mustafa MA, Malathi H, Ahluwalia G, Kaur S, Faisal AN, et al. Nanoparticle-based targeting of pancreatic tumor stroma and extracellular matrix: a promising approach for improved treatment. J Drug Deliv Sci Technol. 2024;99:105938.CrossRef

12.

Li J-X, Huang Q-Y, Zhang J-Y, Du J-Z. Engineering nanoparticles to tackle tumor barriers. J Mater Chem B. 2020;8(31):6686–96.PubMedCrossRef

13.

Lv L, Shi Y, Wu J, Li G. Nanosized drug delivery systems for breast cancer stem cell targeting. Int J Nanomed. 2021;16:1487–508.CrossRef

14.

Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: rationale, clinical data and future perspectives. Cancer Treat Rev. 2016;50:129–41.PubMedCrossRef

15.

Aloss K, Hamar P. Recent preclinical and clinical progress in liposomal doxorubicin. Pharmaceutics. 2023;15(3):893. https://doi.org/10.3390/pharmaceutics15030893.CrossRefPubMedPubMedCentral

16.

Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, et al. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.PubMedPubMedCentralCrossRef

17.

Danenberg E, Bardwell H, Zanotelli VR, Provenzano E, Chin S-F, Rueda OM, et al. Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet. 2022;54(5):660–9.PubMedPubMedCentralCrossRef

18.

Ashrafizadeh M, Farhood B, Eleojo Musa A, Taeb S, Najafi M. The interactions and communications in tumor resistance to radiotherapy: therapy perspectives. Int Immunopharmacol. 2020;87:106807. https://doi.org/10.1016/j.intimp.2020.106807.CrossRefPubMed

19.

Giorello MB, Borzone FR, Labovsky V, Piccioni FV, Chasseing NA. Cancer-associated fibroblasts in the breast tumor microenvironment. J Mammary Gland Biol Neoplasia. 2021;26:135–55.PubMedCrossRef

20.

Elwakeel E, Weigert A. Breast cancer CAFs: spectrum of phenotypes and promising targeting avenues. Int J Mol Sci. 2021;22(21):11636.PubMedPubMedCentralCrossRef

21.

Christodoulatos GS, Spyrou N, Kadillari J, Psallida S, Dalamaga M. The role of adipokines in breast cancer: current evidence and perspectives. Curr Obes Rep. 2019;8:413–33.PubMedCrossRef

22.

Zhang W, Xu J, Fang H, Tang L, Chen W, Sun Q, et al. Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. FASEB J. 2018;32(1):276–88.PubMedCrossRef

23.

Lappano R, Talia M, Cirillo F, Rigiracciolo DC, Scordamaglia D, Guzzi R, et al. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). J Exp Clin Cancer Res. 2020;39:1–22.CrossRef

24.

Hung C-H, Chen F-M, Lin Y-C, Tsai M-L, Wang S-L, Chen Y-C, et al. Altered monocyte differentiation and macrophage polarization patterns in patients with breast cancer. BMC Cancer. 2018;18:1–9.CrossRef

25.

Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol. 2018;51:68–75.PubMedPubMedCentralCrossRef

26.

Ashrafizadeh M, Gholami MH, Mirzaei S, Zabolian A, Haddadi A, Farahani MV, et al. Dual relationship between long non-coding RNAs and STAT3 signaling in different cancers: new insight to proliferation and metastasis. Life Sci. 2021;270:119006.PubMedCrossRef

27.

Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080–9. https://doi.org/10.1111/cas.14069.CrossRefPubMedPubMedCentral

28.

Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547–62.PubMedPubMedCentralCrossRef

29.

Van der Leun AM, Thommen DS, Schumacher TN. CD8+ T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 2020;20(4):218–32.PubMedPubMedCentralCrossRef

30.

Steven A, Seliger B. The role of immune escape and immune cell infiltration in breast cancer. Breast care. 2018;13(1):16–21.PubMedPubMedCentralCrossRef

31.

Gutiérrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends Cancer. 2023;9(4):309–25.PubMedCrossRef

32.

Hajizadeh F, Maleki LA, Alexander M, Mikhailova MV, Masjedi A, Ahmadpour M, et al. Tumor-associated neutrophils as new players in immunosuppressive process of the tumor microenvironment in breast cancer. Life Sci. 2021;264:118699.PubMedCrossRef

33.

Gong YT, Zhang LJ, Liu YC, Tang M, Lin JY, Chen XY, et al. Neutrophils as potential therapeutic targets for breast cancer. Pharmacol Res. 2023. https://doi.org/10.1016/j.phrs.2023.106996.CrossRefPubMed

34.

Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metas. 2019;36(3):171–98.CrossRef

35.

Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart J-B, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Front Oncol. 2020;10:397.PubMedPubMedCentralCrossRef

36.

Lepucki A, Orlińska K, Mielczarek-Palacz A, Kabut J, Olczyk P, Komosińska-Vassev K. The role of extracellular matrix proteins in breast cancer. J Clin Med. 2022;11(5):1250.PubMedPubMedCentralCrossRef

37.

Karamanos NK, Theocharis AD, Piperigkou Z, Manou D, Passi A, Skandalis SS, et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288(24):6850–912.PubMedCrossRef

38.

Corona A, Blobe GC. The role of the extracellular matrix protein TGFBI in cancer. Cell Signal. 2021;84:110028.PubMedCrossRef

39.

Martinez J, Smith PC. The dynamic interaction between extracellular matrix remodeling and breast tumor progression. Cells. 2021;10(5):1046.PubMedPubMedCentralCrossRef

40.

Tomko LA, Hill RC, Barrett A, Szulczewski JM, Conklin MW, Eliceiri KW, et al. Targeted matrisome analysis identifies thrombospondin-2 and tenascin-C in aligned collagen stroma from invasive breast carcinoma. Sci Rep. 2018;8(1):12941.PubMedPubMedCentralCrossRef

41.

Pratt SJ, Lee RM, Martin SS. The mechanical microenvironment in breast cancer. Cancers (Basel). 2020;12(6):1452.PubMedCrossRef

42.

Rigiracciolo DC, Cirillo F, Talia M, Muglia L, Gutkind JS, Maggiolini M, Lappano R. Focal adhesion kinase fine tunes multifaced signals toward breast cancer progression. Cancers (Basel). 2021;13(4):645.PubMedCrossRef

43.

Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu L, et al. Hippo component YAP promotes focal adhesion and tumour aggressiveness via transcriptionally activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer Res. 2018;37:1–17.CrossRef

44.

Li Y, Khuu N, Prince E, Tao H, Zhang N, Chen Z, et al. Matrix stiffness-regulated growth of breast tumor spheroids and their response to chemotherapy. Biomacromol. 2020;22(2):419–29.CrossRef

45.

Han SJ, Kwon S, Kim KS. Contribution of mechanical homeostasis to epithelial-mesenchymal transition. Cell Oncol. 2022;45(6):1119–36.CrossRef

46.

Ondeck MG, Kumar A, Placone JK, Plunkett CM, Matte BF, Wong KC, et al. Dynamically stiffened matrix promotes malignant transformation of mammary epithelial cells via collective mechanical signaling. Proc Natl Acad Sci. 2019;116(9):3502–7.PubMedPubMedCentralCrossRef

47.

Fattet L, Jung H-Y, Matsumoto MW, Aubol BE, Kumar A, Adams JA, et al. Matrix rigidity controls epithelial-mesenchymal plasticity and tumor metastasis via a mechanoresponsive EPHA2/LYN complex. Dev Cell. 2020;54(3):302–16.PubMedPubMedCentralCrossRef

48.

Leggett SE, Hruska AM, Guo M, Wong IY. The epithelial-mesenchymal transition and the cytoskeleton in bioengineered systems. Cell Commun Signal. 2021;19(1):32.PubMedPubMedCentralCrossRef

49.

Hao Y, Baker D, Ten Dijke P. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 2019;20(11):2767.PubMedPubMedCentralCrossRef

50.

Jun BH, Guo T, Libring S, Chanda MK, Paez JS, Shinde A, et al. Fibronectin-expressing mesenchymal tumor cells promote breast cancer metastasis. Cancers (Basel). 2020;12(9):2553.PubMedCrossRef

51.

Ding Y, Liu W, Yu W, Lu S, Liu M, Kaplan DL, Wang X. Three-dimensional tissue culture model of human breast cancer for the evaluation of multidrug resistance. J Tissue Eng Regen Med. 2018;12(9):1959–71.PubMedCrossRef

52.

Wang Y, Goliwas KF, Severino PE, Hough KP, Van Vessem D, Wang H, et al. Mechanical strain induces phenotypic changes in breast cancer cells and promotes immunosuppression in the tumor microenvironment. Lab Invest. 2020;100(12):1503–16.PubMedPubMedCentralCrossRef

53.

Liu R, Luo C, Pang Z, Zhang J, Ruan S, Wu M, et al. Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment. Chin Chem Lett. 2023;34(2):107518.CrossRef

54.

Qi M, Zhou Y. Multimicelle aggregate mechanism for spherical multimolecular micelles: from theories, characteristics and properties to applications. Mater Chem Front. 2019;3(10):1994–2009.CrossRef

55.

Hanafy NA, El-Kemary M, Leporatti S. Micelles structure development as a strategy to improve smart cancer therapy. Cancers (Basel). 2018;10(7):238.PubMedCrossRef

56.

Perumal S, Atchudan R, Lee W. A review of polymeric micelles and their applications. Polymers. 2022;14(12):2510.PubMedPubMedCentralCrossRef

57.

Alavi M, Hamidi M. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles. Drug Metab Personalized Ther. 2019;34(1):20180032.CrossRef

58.

Nasirizadeh S, Malaekeh-Nikouei B. Solid lipid nanoparticles and nanostructured lipid carriers in oral cancer drug delivery. J Drug Deliv Sci Technol. 2020;55:101458.CrossRef

59.

Zhou Y, Zhang Y, Gong H, Luo S, Cui Y. The role of exosomes and their applications in cancer. Int J Mol Sci. 2021;22(22):12204.PubMedPubMedCentralCrossRef

60.

Saluja V, Mishra Y, Mishra V, Giri N, Nayak P. Dendrimers based cancer nanotheranostics: an overview. Int J Pharm. 2021;600:120485.PubMedCrossRef

61.

Sánchez-López E, Guerra M, Dias-Ferreira J, Lopez-Machado A, Ettcheto M, Cano A, et al. Current applications of nanoemulsions in cancer therapeutics. Nanomaterials. 2019;9(6):821.PubMedPubMedCentralCrossRef

62.

Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759–82.PubMedCrossRef

63.

Capek I. Polymer decorated gold nanoparticles in nanomedicine conjugates. Adv Colloid Interface Sci. 2017;249:386–99.PubMedCrossRef

64.

Vallabani NS, Singh S. Recent advances and future prospects of iron oxide nanoparticles in biomedicine and diagnostics. Biotech. 2018;8(6):279.

65.

Vallabani NV, Singh S, Karakoti AS. Magnetic nanoparticles: current trends and future aspects in diagnostics and nanomedicine. Curr Drug Metab. 2019;20(6):457–72.PubMedCrossRef

66.

Guo S, Song Z, Ji D-K, Reina G, Fauny J-D, Nishina Y, et al. Combined photothermal and photodynamic therapy for cancer treatment using a multifunctional graphene oxide. Pharmaceutics. 2022;14(7):1365.PubMedPubMedCentralCrossRef

67.

Naief MF, Mohammed SN, Mayouf HJ, Mohammed AM. A review of the role of carbon nanotubes for cancer treatment based on photothermal and photodynamic therapy techniques. J Organomet Chem. 2023. https://doi.org/10.1016/j.jorganchem.2023.122819.CrossRef

68.

Lagos KJ, Buzzá HH, Bagnato VS, Romero MP. Carbon-based materials in photodynamic and photothermal therapies applied to tumor destruction. Int J Mol Sci. 2021;23(1):22.PubMedPubMedCentralCrossRef

69.

Thomas CS, Kumar Mishra P, Talegaonkar S. Ceramic nanoparticles: fabrication methods and applications in drug delivery. Curr Pharm Des. 2015;21(42):6165–88.PubMedCrossRef

70.

de Almeida MS, Susnik E, Drasler B, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B. Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev. 2021;50(9):5397–434.CrossRef

71.

Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–98.PubMedCrossRef

72.

Baeza A, Ruiz-Molina D, Vallet-Regí M. Recent advances in porous nanoparticles for drug delivery in antitumoral applications: inorganic nanoparticles and nanoscale metal-organic frameworks. Expert Opin Drug Deliv. 2017;14(6):783–96.PubMedCrossRef

73.

Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, et al. Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15(3):191–6. https://doi.org/10.1016/j.clbc.2014.12.003.CrossRefPubMed

74.

Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, et al. NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69–GeparSepto. J Clin Oncol. 2019;37(25):2226–34.PubMedCrossRef

75.

Salazar LG, Lu H, Reichow JL, Childs JS, Coveler AL, Higgins DM, et al. Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017;3(7):969–73.PubMedPubMedCentralCrossRef

76.

McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, et al. A feasibility study of bevacizumab plus dose-dense doxorubicin–cyclophosphamide (AC) followed by nanoparticle albumin–bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011;17(10):3398–407.PubMedPubMedCentralCrossRef

77.

Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer Interdiscip Int J Am Cancer Soc. 2000;89(5):1037–47.

78.

O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9.PubMedCrossRef

79.

Sparano JA, Makhson AN, Semiglazov VF, Tjulandin SA, Balashova OI, Bondarenko IN, et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27(27):4522–9.PubMedCrossRef

80.

Wang H, Li Y, Qi Y, Zhao E, Kong X, Yang C, et al. Pegylated liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant treatment for HER2-positive breast cancer patients: a phase II and biomarker study. Front Oncol. 2022;12:909426.PubMedPubMedCentralCrossRef

81.

Tsai J-H, Li C-L, Yeh D-C, Hung C-S, Hung C-C, Lin C-Y, Kuo Y-L. Neoadjuvant pegylated liposomal doxorubicin- and epirubicin-based combination therapy regimens for early breast cancer: a multicenter retrospective case–control study. Breast Cancer Res Treat. 2023;199(1):47–55. https://doi.org/10.1007/s10549-023-06867-6.CrossRefPubMed

82.

Najafi M, Mortezaee K, Majidpoor J. Stromal reprogramming: a target for tumor therapy. Life Sci. 2019;239:117049.PubMedCrossRef

83.

Lappano R, Rigiracciolo DC, Belfiore A, Maggiolini M, De Francesco EM. Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opin Ther Targets. 2020;24(6):559–72.PubMedCrossRef

84.

Jena BC, Das CK, Banerjee I, Bharadwaj D, Majumder R, Das S, et al. TGF-β1 induced autophagy in cancer associated fibroblasts during hypoxia contributes EMT and glycolysis via MCT4 upregulation. Exp Cell Res. 2022;417(1):113195.PubMedCrossRef

85.

Gialeli C, Nikitovic D, Kletsas D, Theocharis AD, Tzanakakis GN, Karamanos NN. PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts. Curr Pharm Des. 2014;20(17):2843–8.PubMedCrossRef

86.

De Francesco EM, Lappano R, Santolla MF, Marsico S, Caruso A, Maggiolini M. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Res. 2013;15:1–18.CrossRef

87.

Suh J, Kim DH, Lee YH, Jang JH, Surh YJ. Fibroblast growth factor-2, derived from cancer-associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling. Mol Carcinog. 2020;59(9):1028–40.PubMedCrossRef

88.

Taeb S, Ashrafizadeh M, Zarrabi A, Rezapoor S, Musa AE, Farhood B, Najafi M. Role of tumor microenvironment in cancer stem cells resistance to radiotherapy. Curr Cancer Drug Targets. 2022;22(1):18–30.PubMedCrossRef

89.

Ashrafizadeh M, Najafi M, Ang HL, Moghadam ER, Mahabady MK, Zabolian A, et al. PTEN, a barrier for proliferation and metastasis of gastric cancer cells: from molecular pathways to targeting and regulation. Biomedicines. 2020;8(8):264.PubMedPubMedCentralCrossRef

90.

Ashrafizadeh M, Zarrabi A, Samarghandian S, Najafi M. PTEN: what we know of the function and regulation of this onco-suppressor factor in bladder cancer? Eur J Pharmacol. 2020;881:173226.PubMedCrossRef

91.

Huang T-X, Guan X-Y, Fu L. Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells. Am J Cancer Res. 2019;9(9):1889.PubMedPubMedCentral

92.

Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends in Cancer. 2022;8(7):527–55.PubMedCrossRef

93.

Liu S, Ren J, Ten Dijke P. Targeting TGFβ signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6(1):8.PubMedPubMedCentralCrossRef

94.

Li Z, Sun C, Qin Z. Metabolic reprogramming of cancer-associated fibroblasts and its effect on cancer cell reprogramming. Theranostics. 2021;11(17):8322.PubMedPubMedCentralCrossRef

95.

Huang Q, Ge Y, He Y, Wu J, Tong Y, Shang H, et al. The application of nanoparticles targeting cancer-associated fibroblasts. Int J Nanomed. 2024;19:3333–65.CrossRef

96.

Yu Y, Xiao C, Tan L, Wang Q, Li X, Feng Y. Cancer-associated fibroblasts induce epithelial–mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014;110(3):724–32.PubMedCrossRef

97.

Kovács D, Igaz N, Marton A, Rónavári A, Bélteky P, Bodai L, et al. Core–shell nanoparticles suppress metastasis and modify the tumour-supportive activity of cancer-associated fibroblasts. J Nanobiotechnology. 2020;18:1–20.CrossRef

98.

Huang J, Zhang H, Ma L, Ma N, Luo N, Jin W, et al. Rhein and hesperidin nanoparticles remodel tumor immune microenvironment by reducing CAFs and CCL2 secreted by CAAs for efficient triple-negative breast cancer therapy. Int Immunopharmacol. 2024;141:113001. https://doi.org/10.1016/j.intimp.2024.113001.CrossRefPubMed

99.

Yang M, Qin C, Tao L, Cheng G, Li J, Lv F, et al. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment. Biomaterials. 2023;301:122253. https://doi.org/10.1016/j.biomaterials.2023.122253.CrossRefPubMed

100.

Zhang H, Chen L, Zhao Y, Luo N, Shi J, Xu S, et al. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy. Asian J Pharm Sci. 2023;18(2):100796. https://doi.org/10.1016/j.ajps.2023.100796.CrossRefPubMedPubMedCentral

101.

Ji T, Zhao Y, Ding Y, Wang J, Zhao R, Lang J, et al. Transformable peptide nanocarriers for expeditious drug release and effective cancer therapy via cancer-associated fibroblast activation. Angew Chem Int Ed. 2016;55(3):1050–5.CrossRef

102.

Alexander J, Cukierman E. Stromal dynamic reciprocity in cancer: intricacies of fibroblastic-ECM interactions. Curr Opin Cell Biol. 2016;42:80–93.PubMedPubMedCentralCrossRef

103.

Mortezaee K. Normalization in tumor ecosystem: opportunities and challenges. Cell Biol Int. 2021;45(10):2017–30.PubMedCrossRef

104.

Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7:60.PubMedPubMedCentralCrossRef

105.

Karamanos NK, Piperigkou Z, Passi A, Götte M, Rousselle P, Vlodavsky I. Extracellular matrix-based cancer targeting. Trends Mol Med. 2021;27(10):1000–13.PubMedCrossRef

106.

Lorusso G, Rüegg C, Kuonen F. Targeting the extra-cellular matrix—tumor cell crosstalk for anti-cancer therapy: emerging alternatives to integrin inhibitors. Front Oncol. 2020;10:1231.PubMedPubMedCentralCrossRef

107.

Dunshee LC, Sullivan MO, Kiick KL. Therapeutic nanocarriers comprising extracellular matrix-inspired peptides and polysaccharides. Expert Opin Drug Deliv. 2021;18(11):1723–40.PubMedPubMedCentralCrossRef

108.

Goodman TT, Olive PL, Pun SH. Increased nanoparticle penetration in collagenase-treated multicellular spheroids. Int J Nanomed. 2007;2(2):265–74.

109.

Huang HY, Chen LQ, Sun W, Du HH, Dong S, Ahmed AMQ, et al. Collagenase IV and clusterin-modified polycaprolactone-polyethylene glycol nanoparticles for penetrating dense tumor tissues. Theranostics. 2021;11(2):906–24. https://doi.org/10.7150/thno.47446.CrossRefPubMedPubMedCentral

110.

Mauro N, Scialabba C, Puleio R, Varvarà P, Licciardi M, Cavallaro G, Giammona G. SPIONs embedded in polyamino acid nanogels to synergistically treat tumor microenvironment and breast cancer cells. Int J Pharm. 2019;555:207–19. https://doi.org/10.1016/j.ijpharm.2018.11.046.CrossRefPubMed

111.

Abdolahinia ED, Nadri S, Rahbarghazi R, Barar J, Aghanejad A, Omidi Y. Enhanced penetration and cytotoxicity of metformin and collagenase conjugated gold nanoparticles in breast cancer spheroids. Life Sci. 2019;231:116545. https://doi.org/10.1016/j.lfs.2019.116545.CrossRefPubMed

112.

Zhang Y, Han X, Wang K, Liu D, Ding X, Hu Z, Wang J. Co-delivery nanomicelles for potentiating TNBC immunotherapy by synergetically reshaping CAFs-mediated tumor stroma and reprogramming immunosuppressive microenvironment. Int J Nanomed. 2023;18:4329–46. https://doi.org/10.2147/ijn.S418100.CrossRef

113.

Li L, Zhou S, Lv N, Zhen Z, Liu T, Gao S, et al. Photosensitizer-encapsulated ferritins mediate photodynamic therapy against cancer-associated fibroblasts and improve tumor accumulation of nanoparticles. Mol Pharm. 2018;15(8):3595–9. https://doi.org/10.1021/acs.molpharmaceut.8b00419.CrossRefPubMedPubMedCentral

114.

Lu W, Wang N, Liu X, Chen D, Li Q, Rui J, et al. Matrix-degrading soft-nanoplatform with enhanced tissue penetration for amplifying photodynamic therapeutic efficacy of breast cancer. J Mater Chem B. 2024;12(32):7837–47. https://doi.org/10.1039/D4TB00894D.CrossRefPubMed

115.

Qiu Z-W, Zhong Y-T, Lu Z-M, Yan N, Kong R-J, Huang J-Q, et al. Breaking physical barrier of fibrotic breast cancer for photodynamic immunotherapy by remodeling tumor extracellular matrix and reprogramming cancer-associated fibroblasts. ACS Nano. 2024;18(13):9713–35. https://doi.org/10.1021/acsnano.4c01499.CrossRefPubMed

116.

WalshJoseph C, KolbHartmuth C. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21:1516.CrossRef

117.

Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B. 2015;5(5):378–89.PubMedPubMedCentralCrossRef

118.

Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer. 2016;138(5):1058–66.PubMedCrossRef

119.

Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 2019;20(24):6140.PubMedPubMedCentralCrossRef

120.

Hassan Venkatesh G, Abou Khouzam R, Shaaban Moustafa Elsayed W, Ahmed Zeinelabdin N, Terry S, Chouaib S. Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity? Oncoimmunology. 2021;10(1):1974233.PubMedPubMedCentralCrossRef

121.

Mortezaee K, Majidpoor J. Key promoters of tumor hallmarks. Int J Clin Oncol. 2022;27(1):45–58.PubMedCrossRef

122.

Mortezaee K. Hypoxia induces core-to-edge transition of progressive tumoral cells: a critical review on differential yet corroborative roles for HIF-1α and HIF-2α. Life Sci. 2020;242:117145. https://doi.org/10.1016/j.lfs.2019.117145.CrossRefPubMed

123.

Zhang B, Huang X, Wang H, Gou S. Promoting antitumor efficacy by suppressing hypoxia via nano self-assembly of two irinotecan-based dual drug conjugates having a HIF-1α inhibitor. J Mater Chem B. 2019;7(35):5352–62.PubMedCrossRef

124.

Liu X, Sun J, Gu J, Weng L, Wang X, Zhu L, et al. Effective drug and shRNA delivery for synergistic treatment of triple-negative breast cancer by sequentially targeting tumor hypoxia. Chem Eng J. 2023;470:144271.CrossRef

125.

Qannita RA, Alalami AI, Harb AA, Aleidi SM, Taneera J, Abu-Gharbieh E, et al. Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals. 2024;17(2):195.PubMedPubMedCentralCrossRef

126.

Venturelli L, Nappini S, Bulfoni M, Gianfranceschi G, Dal Zilio S, Coceano G, et al. Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells. Sci Rep. 2016;6(1):21629.PubMedPubMedCentralCrossRef

127.

Saadh MJ, Mustafa MA, Qassem LY, Ghadir GK, Alaraj M, Alubiady MHS, et al. Targeting hypoxic and acidic tumor microenvironment by nanoparticles: a review. J Drug Deliv Sci Technol. 2024;96:105660.CrossRef

128.

Cui D, Huang J, Zhen X, Li J, Jiang Y, Pu K. A semiconducting polymer nano-prodrug for hypoxia-activated photodynamic cancer therapy. Angew Chem. 2019;131(18):5981–5.CrossRef

129.

Hao D, Meng Q, Jiang B, Lu S, Xiang X, Pei Q, et al. Hypoxia-activated PEGylated paclitaxel prodrug nanoparticles for potentiated chemotherapy. ACS Nano. 2022;16(9):14693–702.PubMedCrossRef

130.

Li Y, Jeon J, Park JH. Hypoxia-responsive nanoparticles for tumor-targeted drug delivery. Cancer Lett. 2020;490:31–43.PubMedCrossRef

131.

Wang H, Li J, Wang Y, Gong X, Xu X, Wang J, et al. Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy. J Control Release. 2020;319:25–45.PubMedCrossRef

132.

Zhang R, Li Y, Zhang M, Tang Q, Zhang X. Hypoxia-responsive drug–drug conjugated nanoparticles for breast cancer synergistic therapy. RSC Adv. 2016;6(36):30268–76. https://doi.org/10.1039/C6RA01560C.CrossRef

133.

Khan MN, Haggag YA, Lane ME, McCarron PA, Tambuwala MM. Polymeric nano-encapsulation of curcumin enhances its anti-cancer activity in breast (MDA-MB231) and lung (A549) cancer cells through reduction in expression of HIF-1α and nuclear p65 (Rel A). Curr Drug Del. 2018;15(2):286–95. https://doi.org/10.2174/1567201814666171019104002.CrossRef

134.

Li Y, Ding J, Xu X, Shi R, Saw PE, Wang J, et al. Dual hypoxia-targeting RNAi nanomedicine for precision cancer therapy. Nano Lett. 2020;20(7):4857–63. https://doi.org/10.1021/acs.nanolett.0c00757.CrossRefPubMedPubMedCentral

135.

Liu J, Ai X, Cabral H, Liu J, Huang Y, Mi P. Tumor hypoxia-activated combinatorial nanomedicine triggers systemic antitumor immunity to effectively eradicate advanced breast cancer. Biomaterials. 2021;273:120847. https://doi.org/10.1016/j.biomaterials.2021.120847.CrossRefPubMed

136.

Li K, Xu K, He Y, Yang Y, Tan M, Mao Y, et al. Oxygen self-generating nanoreactor mediated ferroptosis activation and immunotherapy in triple-negative breast cancer. ACS Nano. 2023;17(5):4667–87. https://doi.org/10.1021/acsnano.2c10893.CrossRefPubMed

137.

Li H, Yan W, Suo X, Peng H, Yang X, Li Z, et al. Nucleus-targeted nano delivery system eradicates cancer stem cells by combined thermotherapy and hypoxia-activated chemotherapy. Biomaterials. 2019;200:1–14. https://doi.org/10.1016/j.biomaterials.2019.01.048.CrossRefPubMed

138.

Si X, Ma S, Xu Y, Zhang D, Shen N, Yu H, et al. Hypoxia-sensitive supramolecular nanogels for the cytosolic delivery of ribonuclease A as a breast cancer therapeutic. J Control Release. 2020;320:83–95. https://doi.org/10.1016/j.jconrel.2020.01.021.CrossRefPubMed

139.

Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors-clinical perspectives. Cell Oncol. 2021;44:715–37.CrossRef

140.

Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9.PubMedPubMedCentralCrossRef

141.

Michaelis UR. Mechanisms of endothelial cell migration. Cell Mol Life Sci. 2014;71:4131–48.PubMedPubMedCentralCrossRef

142.

Al-Ostoot FH, Salah S, Khamees HA, Khanum SA. Tumor angiogenesis: current challenges and therapeutic opportunities. Cancer Treat Res Commun. 2021;28:100422.PubMedCrossRef

143.

Badodekar N, Sharma A, Patil V, Telang G, Sharma R, Patil S, et al. Angiogenesis induction in breast cancer: a paracrine paradigm. Cell Biochem Funct. 2021;39(7):860–73.PubMedCrossRef

144.

Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci. 2015;112(46):14325–30.PubMedPubMedCentralCrossRef

145.

Qin L, Wu J. Targeting anticancer immunity in oral cancer: drugs, products, and nanoparticles. Environ Res. 2023;239:116751.PubMedCrossRef

146.

Wang F, Li C, Cheng J, Yuan Z. Recent advances on inorganic nanoparticle-based cancer therapeutic agents. Int J Environ Res Public Health. 2016;13(12):1182.PubMedPubMedCentralCrossRef

147.

Ghalamfarsa G, Rastegari A, Atyabi F, Hassannia H, Hojjat-Farsangi M, Ghanbari A, et al. Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. J Cell Physiol. 2018;233(10):7165–77. https://doi.org/10.1002/jcp.26743.CrossRefPubMed

148.

Chen J, Sun X, Shao R, Xu Y, Gao J, Liang W. VEGF siRNA delivered by polycation liposome-encapsulated calcium phosphate nanoparticles for tumor angiogenesis inhibition in breast cancer. Int J Nanomed. 2017;12:6075–88.CrossRef

149.

Dawood DH, Abbas EMH, Farghaly TA, Ali MM, Ibrahim MF. ZnO nanoparticles catalyst in the synthesis of bioactive fused pyrimidines as anti-breast cancer agents targeting VEGFR-2. Med Chem. 2019;15(3):277–86. https://doi.org/10.2174/1573406414666180912113226.CrossRefPubMed

150.

Shashni B, Nishikawa Y, Nagasaki Y. Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles. Biomaterials. 2021;269:120645. https://doi.org/10.1016/j.biomaterials.2020.120645.CrossRefPubMed

151.

Zhang P-L, Hou X-X, Liu M-R, Huang F-P, Qin X-Y. Two novel chiral tetranucleate copper-based complexes: crystal structures, nanoparticles, and inhibiting angiogenesis and the growth of human breast cancer by regulating the VEGF/VEGFR2 signal pathway in vitro. Dalton Trans. 2020;49(18):6043–55. https://doi.org/10.1039/D0DT00380H.CrossRefPubMed

152.

Semkina AS, Abakumov MA, Skorikov AS, Abakumova TO, Melnikov PA, Grinenko NF, et al. Multimodal doxorubicin loaded magnetic nanoparticles for VEGF targeted theranostics of breast cancer. Nanomed Nanotechnol Biol Med. 2018;14(5):1733–42. https://doi.org/10.1016/j.nano.2018.04.019.CrossRef

153.

Feng Q, Yu M-Z, Wang J-C, Hou W-J, Gao L-Y, Ma X-F, et al. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core–shell nanoparticles. Biomaterials. 2014;35(18):5028–38. https://doi.org/10.1016/j.biomaterials.2014.03.012.CrossRefPubMed

154.

Jin M, Jin G, Kang L, Chen L, Gao Z, Huang W. Smart polymeric nanoparticles with pH-responsive and PEG-detachable properties for co-delivering paclitaxel and survivin siRNA to enhance antitumor outcomes. Int J Nanomed. 2018;13:2405–26.CrossRef

155.

Dong J, Yao X, Sun S, Zhong Y, Qian C, Yang D. In vivo targeting of breast cancer with a vasculature-specific GQDs/hMSN nanoplatform. RSC Adv. 2019;9(20):11576–84.PubMedPubMedCentralCrossRef

156.

Chen W-H, Yang Sung S, Fadeev M, Cecconello A, Nechushtai R, Willner I. Targeted VEGF-triggered release of an anti-cancer drug from aptamer-functionalized metal–organic framework nanoparticles. Nanoscale. 2018;10(10):4650–7. https://doi.org/10.1039/C8NR00193F.CrossRefPubMed

157.

Mpekris F, Panagi M, Voutouri C, Martin JD, Samuel R, Takahashi S, et al. Normalizing the microenvironment overcomes vessel compression and resistance to nano-immunotherapy in breast cancer lung metastasis. Adv Sci. 2021;8(3):2001917.CrossRef

158.

Luo X, Zou W, Wei Z, Yu S, Zhao Y, Wu Y, et al. Inducing vascular normalization: a promising strategy for immunotherapy. Int Immunopharmacol. 2022;112:109167.PubMedCrossRef

159.

Xiao W, Ruan S, Yu W, Wang R, Hu C, Liu R, Gao H. Normalizing tumor vessels to increase the enzyme-induced retention and targeting of gold nanoparticle for breast cancer imaging and treatment. Mol Pharm. 2017;14(10):3489–98.PubMedCrossRef

160.

Li W, Li X, Liu S, Yang W, Pan F, Yang XY, et al. Gold nanoparticles attenuate metastasis by tumor vasculature normalization and epithelial–mesenchymal transition inhibition. Int J Nanomed. 2017;12:3509–20.CrossRef

161.

Huang N, Liu Y, Fang Y, Zheng S, Wu J, Wang M, et al. Gold nanoparticles induce tumor vessel normalization and impair metastasis by inhibiting endothelial Smad2/3 signaling. ACS Nano. 2020;14(7):7940–58. https://doi.org/10.1021/acsnano.9b08460.CrossRefPubMed

162.

Palange AL, Di Mascolo D, Carallo C, Gnasso A, Decuzzi P. Lipid-polymer nanoparticles encapsulating curcumin for modulating the vascular deposition of breast cancer cells. Nanomedicine. 2014;10(5):991–1002. https://doi.org/10.1016/j.nano.2014.02.004.CrossRefPubMed

163.

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021;11:610303.PubMedPubMedCentralCrossRef

164.

Liu H, Wang Z, Zhou Y, Yang Y. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Front Immunol. 2023;14:1199273.PubMedPubMedCentralCrossRef

165.

Fjørtoft MO, Huse K, Rye IH. The tumor immune microenvironment in breast cancer progression. Acta Oncol. 2024;63:33008.

166.

Baxevanis CN, Fortis SP, Perez SA. The balance between breast cancer and the immune system: challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2021;72:76–89.PubMedCrossRef

167.

He Y, de Araújo Júnior RF, Cruz LJ, Eich C. Functionalized nanoparticles targeting tumor-associated macrophages as cancer therapy. Pharmaceutics. 2021;13(10):1670.PubMedPubMedCentralCrossRef

168.

Tuettenberg A, Steinbrink K, Schuppan D. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy. Nanomedicine. 2016;11(20):2735–51.PubMedCrossRef

169.

Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res. 2022;41(1):68.PubMedPubMedCentralCrossRef

170.

Lu Z, Liu H, Ma L, Ren K, He Z, Li M, He Q. Micellar nanoparticles inhibit breast cancer and pulmonary metastasis by modulating the recruitment and depletion of myeloid-derived suppressor cells. Nanoscale. 2022;14(46):17315–30. https://doi.org/10.1039/D2NR03880C.CrossRefPubMed

171.

Yoon J, Le XT, Kim J, Lee H, Nguyen NT, Lee WT, et al. Macrophage-reprogramming upconverting nanoparticles for enhanced TAM-mediated antitumor therapy of hypoxic breast cancer. J Control Release. 2023;360:482–95. https://doi.org/10.1016/j.jconrel.2023.07.009.CrossRefPubMed

172.

Guo C, Su Y, Wang B, Chen Q, Guo H, Kong M, Chen D. Novel polysaccharide building hybrid nanoparticles: remodelling TAMs to target ERα-positive breast cancer. J Drug Target. 2022;30(4):450–62.PubMedCrossRef

173.

Liu Y, Zhang D, Zhang Z, Liang X, Yang X, Ding N, et al. Multifunctional nanoparticles inhibit tumor and tumor-associated macrophages for triple-negative breast cancer therapy. J Colloid Interface Sci. 2024;657:598–610. https://doi.org/10.1016/j.jcis.2023.11.156.CrossRefPubMed

174.

Song Y, Tang C, Yin C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials. 2018;185:117–32. https://doi.org/10.1016/j.biomaterials.2018.09.017.CrossRefPubMed

175.

Cavalcante RS, Ishikawa U, Silva ES, Silva-Júnior AA, Araújo AA, Cruz LJ, et al. STAT3/NF-κB signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. Br J Pharmacol. 2021;178(11):2284–304.PubMedCrossRef

176.

Chen H, Luan X, Paholak HJ, Burnett JP, Stevers NO, Sansanaphongpricha K, et al. Depleting tumor-associated Tregs via nanoparticle-mediated hyperthermia to enhance anti-CTLA-4 immunotherapy. Nanomed (Lond). 2020;15(1):77–92. https://doi.org/10.2217/nnm-2019-0190.CrossRef

177.

Masoumi E, Tahaghoghi-Hajghorbani S, Jafarzadeh L, Sanaei M-J, Pourbagheri-Sigaroodi A, Bashash D. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. J Control Release. 2021;340:168–87.PubMedCrossRef

178.

Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAA, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170(6):1120–33.PubMedPubMedCentralCrossRef

179.

Yang A, Dong X, Bai Y, Sheng S, Zhang Y, Liu T, et al. Doxorubicin/CpG self-assembled nanoparticles prodrug and dendritic cells co-laden hydrogel for cancer chemo-assisted immunotherapy. Chem Eng J. 2021;416:129192.CrossRef

180.

Zheng X, Koropatnick J, Chen D, Velenosi T, Ling H, Zhang X, et al. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model. Int J Cancer. 2013;132(4):967–77.PubMedCrossRef

181.

Kim KS, Kim DH, Kim DH. Recent advances to augment NK cell cancer immunotherapy using nanoparticles. Pharmaceutics. 2021;13(4):525.PubMedPubMedCentralCrossRef

182.

Wu Y, Gu W, Li J, Chen C, Xu ZP. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes. Nanomedicine. 2019;14(8):955–67.PubMedCrossRef

183.

Camorani S, Tortorella S, Agnello L, Spanu C, d’Argenio A, Nilo R, et al. Aptamer-functionalized nanoparticles mediate PD-L1 siRNA delivery for effective gene silencing in triple-negative breast cancer cells. Pharmaceutics. 2022;14(10):2225.PubMedPubMedCentralCrossRef

184.

Taghavi Pourianazar N, Gunduz U. Changes in apoptosis-related gene expression and cytokine release in breast cancer cells treated with CpG-loaded magnetic PAMAM nanoparticles. Int J Pharm. 2016;515(1):11–9. https://doi.org/10.1016/j.ijpharm.2016.10.007.CrossRefPubMed

185.

Pacheco-Torres J, Penet MF, Krishnamachary B, Mironchik Y, Chen Z, Bhujwalla ZM. PD-L1 siRNA Theranostics with a dextran nanoparticle highlights the importance of nanoparticle delivery for effective tumor PD-L1 downregulation. Front Oncol. 2021. https://doi.org/10.3389/fonc.2020.614365.CrossRefPubMedPubMedCentral

186.

Cheng Y, Wang C, Wang H, Zhang Z, Yang X, Dong Y, et al. Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy. BMC Med. 2022;20(1):411.PubMedPubMedCentralCrossRef

187.

Liu X, Wang H, Li Z, Li J, He S, Hu C, et al. Transformable self-delivered supramolecular nanomaterials combined with anti-PD-1 antibodies alleviate tumor immunosuppression to treat breast cancer with bone metastasis. J Nanobiotechnology. 2024;22(1):566.PubMedPubMedCentralCrossRef

188.

Duan X, Chan C, Guo N, Han W, Weichselbaum RR, Lin W. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. J Am Chem Soc. 2016;138(51):16686–95. https://doi.org/10.1021/jacs.6b09538.CrossRefPubMedPubMedCentral

189.

Gu F, Hu C, Cao W, Li C, Xia Q, Gao Y, et al. Tumor microenvironment multiple responsive nanoparticles for targeted delivery of doxorubicin and CpG against triple-negative breast cancer. Int J Nanomed. 2022;17:4401–17. https://doi.org/10.2147/ijn.S377702.CrossRef

190.

Chen C, Guo Q, Fu H, Yu J, Wang L, Sun Y, et al. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials. 2021;275:120988. https://doi.org/10.1016/j.biomaterials.2021.120988.CrossRefPubMed

191.

Yu G, Dong F, Ge W, Sun L, Zhang L, Yuan L, et al. Self-assembled nanospheres mediate phototherapy and deliver CpG oligodeoxynucleotides to enhance cancer immunotherapy of breast cancer and melanoma. Nano Today. 2022;44:101498. https://doi.org/10.1016/j.nantod.2022.101498.CrossRef

192.

Zhang X, Wu F, Men K, Huang R, Zhou B, Zhang R. Modified Fe3O4 magnetic nanoparticle delivery of CpG inhibits tumor growth and spontaneous pulmonary metastases to enhance immunotherapy. Nanoscale Res Lett. 2018;13:240.PubMedPubMedCentralCrossRef

193.

Fang Z, Wan L-Y, Chu L-Y, Zhang Y-Q, Wu J-F. ‘Smart’nanoparticles as drug delivery systems for applications in tumor therapy. Expert Opin Drug Deliv. 2015;12(12):1943–53.PubMedCrossRef

194.

Liu D, Yang F, Xiong F, Gu N. The smart drug delivery system and its clinical potential. Theranostics. 2016;6(9):1306.PubMedPubMedCentralCrossRef

195.

Jia L, Zhang P, Sun H, Dai Y, Liang S, Bai X, Feng L. Optimization of nanoparticles for smart drug delivery: a review. Nanomaterials. 2021;11(11):2790.PubMedPubMedCentralCrossRef

196.

Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A. Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines. 2022;13(10):1623.PubMedPubMedCentralCrossRef

197.

Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8(1):418.PubMedPubMedCentralCrossRef

198.

Farhood B, Ashrafizadeh M, Hoseini-Ghahfarokhi M, Afrashi S, Musa AE, Najafi M. Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sci. 2020;250:117570.PubMedCrossRef

199.

Bogdanov A, Bogdanov A, Chubenko V, Volkov N, Moiseenko F, Moiseyenko V. Tumor acidity: from hallmark of cancer to target of treatment. Front Oncol. 2022;12:979154.PubMedPubMedCentralCrossRef

200.

Piasentin N, Milotti E, Chignola R. The control of acidity in tumor cells: a biophysical model. Sci Rep. 2020;10(1):13613.PubMedPubMedCentralCrossRef

201.

Chiche J, Ilc K, Laferriere J, Trottier E, Dayan F, Mazure NM, et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res. 2009;69(1):358–68.PubMedCrossRef

202.

Spugnini EP, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, et al. Proton channels and exchangers in cancer. Biochimica et Biophysica Acta (BBA) Biomembr. 2015;1848(10):2715–26.CrossRef

203.

Counillon L, Bouret Y, Marchiq I. Pouysségur J (2016) Na+/H+ antiporter (NHE1) and lactate/H+ symporters (MCTs) in pH homeostasis and cancer metabolism. Biochimica et Biophysica Acta (BBA) Mol Cell Res. 1863;10:2465–80.

204.

Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev. 2019;38:113–29.PubMedCrossRef

205.

Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, et al. Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation. In: Seminars in cancer biology. Amsterdam: Elsevier; 2017. p. 74–89.

206.

Yang H, Tang C, Yin C. Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer. Acta Biomater. 2018;73:400–11. https://doi.org/10.1016/j.actbio.2018.04.020.CrossRefPubMed

207.

Duo Y, Li Y, Chen C, Liu B, Wang X, Zeng X, Chen H. DOX-loaded pH-sensitive mesoporous silica nanoparticles coated with PDA and PEG induce pro-death autophagy in breast cancer. RSC Adv. 2017;7(63):39641–50.CrossRef

208.

Tang S, Yin Q, Su J, Sun H, Meng Q, Chen Y, et al. Inhibition of metastasis and growth of breast cancer by pH-sensitive poly (β-amino ester) nanoparticles co-delivering two siRNA and paclitaxel. Biomaterials. 2015;48:1–15. https://doi.org/10.1016/j.biomaterials.2015.01.049.CrossRefPubMed

209.

Yin J, Lang T, Cun D, Zheng Z, Huang Y, Yin Q, et al. pH-sensitive nano-complexes overcome drug resistance and inhibit metastasis of breast cancer by silencing akt expression. Theranostics. 2017;7(17):4204–16. https://doi.org/10.7150/thno.21516.CrossRefPubMedPubMedCentral

210.

Zhang T, Liu H, Li Y, Li C, Wan G, Chen B, et al. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition. Acta Biomater. 2019;99:412–25. https://doi.org/10.1016/j.actbio.2019.09.001.CrossRefPubMed

211.

Tao J, Diao L, Chen F, Shen A, Wang S, Jin H, et al. pH-sensitive nanoparticles codelivering docetaxel and dihydroartemisinin effectively treat breast cancer by enhancing reactive oxidative species-mediated mitochondrial apoptosis. Mol Pharm. 2021;18(1):74–86. https://doi.org/10.1021/acs.molpharmaceut.0c00432.CrossRefPubMed

212.

Yuan J-D, ZhuGe D-L, Tong M-Q, Lin M-T, Xu X-F, Tang X, et al. pH-sensitive polymeric nanoparticles of mPEG-PLGA-PGlu with hybrid core for simultaneous encapsulation of curcumin and doxorubicin to kill the heterogeneous tumour cells in breast cancer. Artif Cells Nanomed Biotechnol. 2018;46(1):302–13.PubMedCrossRef

213.

Tao J, Tan Z, Diao L, Ji Z, Zhu J, Chen W, Hu Y. Co-delivery of dihydroartemisinin and docetaxel in pH-sensitive nanoparticles for treating metastatic breast cancer via the NF-κB/MMP-2 signal pathway. RSC Adv. 2018;8(39):21735–44.PubMedPubMedCentralCrossRef

214.

Jacob A, Prekeris R. The regulation of MMP targeting to invadopodia during cancer metastasis. Front Cell Dev Biol. 2015;3:4.PubMedPubMedCentralCrossRef

215.

Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015;2(1):26–34.PubMedPubMedCentralCrossRef

216.

Kwon MJ. Matrix metalloproteinases as therapeutic targets in breast cancer. Front Oncol. 2023;12:1108695.PubMedPubMedCentralCrossRef

217.

Yao Q, Kou L, Tu Y, Zhu L. MMP-responsive ‘smart’drug delivery and tumor targeting. Trends Pharmacol Sci. 2018;39(8):766–81.PubMedCrossRef

218.

Xu Y, Zhang J, Liu X, Huo P, Zhang Y, Chen H, et al. MMP-2-responsive gelatin nanoparticles for synergistic tumor therapy. Pharm Dev Technol. 2019;24(8):1002–13. https://doi.org/10.1080/10837450.2019.1621899.CrossRefPubMed

219.

Shargh VH, Hondermarck H, Liang M. Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy. Nanomedicine. 2017;12(9):977–89. https://doi.org/10.2217/nnm-2016-0419.CrossRefPubMed

220.

Chen X, Zou J, Zhang K, Zhu J, Zhang Y, Zhu Z, et al. Photothermal/matrix metalloproteinase-2 dual-responsive gelatin nanoparticles for breast cancer treatment. Acta Pharm Sin B. 2021;11(1):271–82. https://doi.org/10.1016/j.apsb.2020.08.009.CrossRefPubMed

221.

Raman D, Foo CHJ, Clement M-V, Pervaiz S. Breast cancer: a molecular and redox snapshot. Antioxid Redox Signal. 2016;25(6):337–70.PubMedCrossRef

222.

Sadowska-Bartosz I, Bartosz G. Redox nanoparticles: synthesis, properties and perspectives of use for treatment of neurodegenerative diseases. J Nanobiotechnology. 2018;16:1–16.CrossRef

223.

Mazzotta E, De Benedittis S, Qualtieri A, Muzzalupo R. Actively targeted and redox responsive delivery of anticancer drug by chitosan nanoparticles. Pharmaceutics. 2019;12(1):26.PubMedPubMedCentralCrossRef

224.

Li N, Wang Z, Zhang Y, Zhang K, Xie J, Liu Y, et al. Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(2):921–35.PubMedCrossRef

225.

Rezaei S, Kashanian S, Bahrami Y, Cruz LJ, Motiei M. Redox-sensitive and hyaluronic acid-functionalized nanoparticles for improving breast cancer treatment by cytoplasmic 17α-methyltestosterone delivery. Molecules. 2020;25(5):1181.PubMedPubMedCentralCrossRef

226.

Wang R, Yang H, Khan AR, Yang X, Xu J, Ji J, Zhai G. Redox-responsive hyaluronic acid-based nanoparticles for targeted photodynamic therapy/chemotherapy against breast cancer. J Colloid Interface Sci. 2021;598:213–28. https://doi.org/10.1016/j.jcis.2021.04.056.CrossRefPubMed

227.

Shi J, Ren Y, Ma J, Luo X, Li J, Wu Y, et al. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core–shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis. J Nanobiotechnology. 2021;19(1):188.PubMedPubMedCentralCrossRef

228.

Zhao YP, Ye WL, Liu DZ, Cui H, Cheng Y, Liu M, et al. Redox and pH dual sensitive bone targeting nanoparticles to treat breast cancer bone metastases and inhibit bone resorption. Nanoscale. 2017;9(19):6264–77. https://doi.org/10.1039/C7NR00962C.CrossRefPubMed

229.

Zhou K, Zhu Y, Chen X, Li L, Xu W. Redox- and MMP-2-sensitive drug delivery nanoparticles based on gelatin and albumin for tumor targeted delivery of paclitaxel. Mater Sci Eng C. 2020;114:111006. https://doi.org/10.1016/j.msec.2020.111006.CrossRef

230.

Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother. 2007;56:1687–700.PubMedPubMedCentralCrossRef

231.

Peyton SR, Platt MO, Cukierman E. Challenges and opportunities modeling the dynamic tumor matrisome. BME Front. 2023;4:0006.PubMedPubMedCentralCrossRef

232.

He X, Yang Y, Han Y, Cao C, Zhang Z, Li L, et al. Extracellular matrix physical properties govern the diffusion of nanoparticles in tumor microenvironment. Proc Natl Acad Sci. 2023;120(1):e2209260120.PubMedCrossRef

233.

Park J, Choi Y, Chang H, Um W, Ryu JH, Kwon IC. Alliance with EPR effect: combined strategies to improve the EPR effect in the tumor microenvironment. Theranostics. 2019;9(26):8073.PubMedPubMedCentralCrossRef

234.

Sundaram A, Peng L, Chai L, Xie Z, Ponraj JS, Wang X, et al. Advanced nanomaterials for hypoxia tumor therapy: challenges and solutions. Nanoscale. 2020;12(42):21497–518.PubMedCrossRef

235.

Koltai T. The complex relationship between multiple drug resistance and the tumor pH gradient: a review. Cancer Drug Resist. 2022;5(2):277.PubMedPubMedCentralCrossRef

236.

Bi J, Mo C, Li S, Huang M, Lin Y, Yuan P, et al. Immunotoxicity of metal and metal oxide nanoparticles: from toxic mechanisms to metabolism and outcomes. Biomater Sci. 2023;11(12):4151–83.PubMedCrossRef

237.

Shegokar R, Nakach M. Large-scale manufacturing of nanoparticles—an industrial outlook. Drug delivery aspects. Amsterdam: Elsevier; 2020. p. 57–77.

238.

Gupta R, Xie H. Nanoparticles in daily life: applications, toxicity and regulations. J Environ Pathol Toxicol Oncol. 2018;37(3):209–30.PubMedPubMedCentralCrossRef

239.

Ha M, Kim J-H, You M, Li Q, Fan C, Nam J-M. Multicomponent plasmonic nanoparticles: from heterostructured nanoparticles to colloidal composite nanostructures. Chem Rev. 2019;119(24):12208–78.PubMedCrossRef

240.

Wang S, Cheng K, Chen K, Xu C, Ma P, Dang G, et al. Nanoparticle-based medicines in clinical cancer therapy. Nano Today. 2022;45:101512.CrossRef

241.

Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic nanoparticles and their targeted delivery applications. Molecules. 2020;25(9):2193.PubMedPubMedCentralCrossRef

242.

Muheem A, Jahangir MA, Jaiswal CP, Jafar M, Ahmad MZ, Ahmad J, Warsi MH. Recent patents, regulatory issues, and toxicity of nanoparticles in neuronal disorders. Curr Drug Metab. 2021;22(4):263–79.PubMed

243.

Confeld MI, Mamnoon B, Feng L, Jensen-Smith H, Ray P, Froberg J, et al. Targeting the tumor core: hypoxia-responsive nanoparticles for the delivery of chemotherapy to pancreatic tumors. Mol Pharm. 2020;17(8):2849–63.PubMedPubMedCentralCrossRef

244.

Paris JL, Baeza A, Vallet-Regí M. Overcoming the stability, toxicity, and biodegradation challenges of tumor stimuli-responsive inorganic nanoparticles for delivery of cancer therapeutics. Expert Opin Drug Deliv. 2019;16(10):1095–112.PubMedCrossRef

Title: Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles
Authors: Faris Anad Muhammad
Farag M. A. Altalbawy
Viralkumar Mandaliya
Shelesh Krishna Saraswat
M. M. Rekha
Damanjeet Aulakh
Mamata Chahar
Morug Salih Mahdi
Mohammed Adil Jaber
Merwa Alhadrawi
Publication date: 18-12-2024
Publisher: Springer International Publishing
Keywords: Breast Cancer
Breast Cancer
Published in: Clinical and Translational Oncology
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-024-03793-x

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Targeted Therapy
On-demand webinar

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Podcast | Sexual health in older age

Springer Medicine

Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles

Abstract

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content

Elevate your expertise in aplastic anemia (Link opens in a new window)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma